Why test for ESR1 mutations?
HR+/HER2- advanced or metastatic breast cancer is a dynamic disease with the potential to develop genetic mutations. In this video, Dr. Anne O’Dea, Associate Professor at the University of Kansas School of Medicine, USA, discuses the mechanisms behind endocrineresistance and how testing for ESR1 mutations can provide valuable prognostic information, helping to guide treatment decisions.
Why test for ESR1 mutations?
Dr. Anne O'Dea, MD
